The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.

[1]  F. Borrelli,et al.  Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  G. Fur,et al.  In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum , 1998, British journal of pharmacology.

[3]  R. Pertwee,et al.  Comparison of cannabinoid binding sites in guinea‐pig forebrain and small intestine , 1998, British journal of pharmacology.

[4]  A. Izzo,et al.  Recent findings on the mode of action of laxatives: the role of platelet activating factor and nitric oxide. , 1998, Trends in pharmacological sciences.

[5]  F. Borrelli,et al.  Excitatory transmission to the circular muscle of the guinea‐pig ileum: evidence for the involvement of cannabinoid CB1 receptors , 1998, British journal of pharmacology.

[6]  D. Bonhaus,et al.  Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors , 1998, British journal of pharmacology.

[7]  G. Gessa,et al.  Cannabinoid modulation of intestinal propulsion in mice. , 1998, European journal of pharmacology.

[8]  P. Casellas,et al.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[9]  D. Piomelli,et al.  Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. , 1997, European journal of pharmacology.

[10]  S. Yu,et al.  Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. , 1997, European journal of pharmacology.

[11]  R. Pertwee.  Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[12]  J. Nash,et al.  Further evidence for the presence of cannabinoid CB1 receptors in guinea‐pig small intestine , 1996, British journal of pharmacology.

[13]  I. McGregor,et al.  Aversive effects of the synthetic cannabinoid CP 55,940 in rats , 1996, Pharmacology Biochemistry and Behavior.

[14]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[15]  P. Soubrié,et al.  Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. , 1995, Life sciences.

[16]  A. Howlett,et al.  Pharmacology of cannabinoid receptors. , 1995, Annual review of pharmacology and toxicology.

[17]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[18]  J. Bakalar,et al.  Marihuana: The Forbidden Medicine , 1993 .

[19]  A. Izzo,et al.  Inhibitors of nitric oxide synthetase prevent castor‐oil‐induced diarrhoea in the rat , 1993, British journal of pharmacology.

[20]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[21]  L. Gold,et al.  Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. , 1992, The Journal of pharmacology and experimental therapeutics.

[22]  N. Kaminski,et al.  Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. , 1992, Molecular pharmacology.

[23]  T. Croci,et al.  Stimulation of faecal excretion in rats by α2‐adrenergic antagonists , 1992 .

[24]  G Vassart,et al.  Molecular cloning of a human cannabinoid receptor which is also expressed in testis. , 1991, The Biochemical journal.

[25]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.